Supreme Court Hears Wyeth v. Levine Drug Pre-Emption Case
This article was originally published in The Gray Sheet
Executive Summary
U.S. Supreme Court justices focused their questioning during Nov. 3 oral arguments in the case of Wyeth v. Levine on the specific risk-benefit trade-off for the drug in question, but also addressed broader principles of FDA policy
You may also be interested in...
Wyeth Supreme Court Case Could Have Impact On Device Suits, Lawyers Say
If the Supreme Court favors "implied" federal pre-emption for FDA-approved pharmaceutical labeling in a case that will be heard by the court next month, some devices may receive additional protections too, lawyers suggest
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.